September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Randomized Clinical Trial Evaluating Reflux, IOP, and Pain, Following Intravitreal Anti Vascular Endothelial Growth Factors Injections Using 30g and 32g Needles
Author Affiliations & Notes
  • Saeed Alshahrani
    Ophthlamology, King Fahad Specialist Hospital-Dammam, Riyadh, Saudi Arabia
    Ophthalmology, Queens university, Kingston, Ontario, Canada
  • Vasudha Gupta
    Ophthalmology, Queens university, Kingston, Ontario, Canada
  • Uriel Rubin
    Ophthalmology, Queens university, Kingston, Ontario, Canada
  • Tom Gonder
    Ophthalmology, Queens university, Kingston, Ontario, Canada
  • Isabella Irrcher
    Ophthalmology, Queens university, Kingston, Ontario, Canada
  • Sanjay Sharma
    Ophthalmology, Queens university, Kingston, Ontario, Canada
  • Footnotes
    Commercial Relationships   Saeed Alshahrani, None; Vasudha Gupta, None; Uriel Rubin, None; Tom Gonder, None; Isabella Irrcher, None; Sanjay Sharma, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 552. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Saeed Alshahrani, Vasudha Gupta, Uriel Rubin, Tom Gonder, Isabella Irrcher, Sanjay Sharma; Randomized Clinical Trial Evaluating Reflux, IOP, and Pain, Following Intravitreal Anti Vascular Endothelial Growth Factors Injections Using 30g and 32g Needles. Invest. Ophthalmol. Vis. Sci. 2016;57(12):552.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the differences in reflux, IOP and pain scores, between intravitreal injections (IVI) performed with 30g and 32g needles.

Methods : A prospective, randomized interventional study of patients who required bilatetal intravitreal anti-VEGF injection (n=61). One eye was randomized to receive a 30g needle and the contralateral eye to 32 g. Immediate postinjection reflux, our primary outcome, was noted at he time of injection and recorded as a binary outcome (yes or no); pain was quantified using a VAS pain scale and IOP pressure was measure before and 5 minutes after IVI. Our study was designed to detect a 10% difference in the proportion of patients with reflux, assuming an alpha of 0.05 and power of 80%.

Results : Postinjection reflux was present 40% in 30G and 24% in those who recieved injection with a 32G needle (x2=4.5; p-value = 0.033). A trend was noted whereby eyes randomized to 32 g needle had less pain (31% reported no pain as compared to 23% in the 30 g Group). A trend was noted for a higher IOP with a 31% elevation in the 32 g Group, as compared to 25% in the 30 g Group. On average, patients preferred the 32 g needle.

Conclusions : In this study, 32 g Needles are associated with less postinjection reflux, a trend toward less pain, but a trend towards a transient increase in IOP. A patient preference for 32 g Needles was noted.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×